Roger Amigo, DO
Urology · Bellefontaine, OHNPI 1982603668
Payments from drug & device makers
Across 9 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$30
- Boston Scientific$26
- Sumitomo Pharma America, Inc.$25
- Tolmar Pharmaceuticals, Inc.$24
- Tolmar, Inc.$19
- Urovant Sciences Inc$16
What the payments were for
- Food & beverage$141100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 1 | $30 |
| Boston Scientific | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $19 |
| Urovant Sciences Inc | 1 | $16 |
| Innovative Medical Technologies, LLC | 3 | $0 |
How this compares
$141 in reported general payments places this provider in the 10th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 127 | $77,763 |
| Solifenacin Succinate | 113 | $8,020 |
| Tolterodine Tartrate | 69 | $7,340 |
| Tamsulosin Hcl | 533 | $7,274 |
| Finasteride | 440 | $5,727 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 28 | $4,591 |
| Oxybutynin Chloride | 239 | $3,587 |
| Testosterone Cypionate | 53 | $3,211 |
| Oxybutynin Chloride ErOxybutynin Chloride | 135 | $2,913 |
| NitrofurantoinNitrofurantoin Macrocrystal | 52 | $2,903 |
| Trospium Chloride | 28 | $2,680 |
| Tolterodine Tartrate ErTolterodine Tartrate | 33 | $2,431 |
| Testosterone | 35 | $2,379 |
| Bethanechol Chloride | 36 | $2,234 |
| Dutasteride | 29 | $830 |
Paid to pharmacies, not to this prescriber.
Other urology in Bellefontaine
- Marc PliskinCincinnati$20.8M
- Lawrence GervasiMiddleburg Heights$4.7M
- Martin FritzhandCincinnati$4.6M
- Kamal PoharCincinnati$3.4M
- Eric SingerColumbus$2.1M
- Benjamin MartinGahanna$1.1M
- Howard GoldmanCleveland$747K
- Jihad KaoukCleveland$696K
- Raymond RackleyCleveland$695K
- Sandip VasavadaCleveland$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.